Αρχική World News Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell Lung...

Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell Lung Cancer

In an updated integrated analysis of three phase I or II clinical studies ALKA-372-001, STARTRK-1, and STARTRK-2, comprising more patients and a longer follow-up than the primary analysis, entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion–positive locally advanced or metastatic non-small cell lung cancer (NSCLC), including those with central nervous system (CNS) metastases at baseline. A high proportion of enrolled patients were pretreated and had CNS metastases at baseline, highlighting the relatively poor prognostic population included in the study. The findings from this largest prospective study in that population are published by Prof. Fabrice Barlesi of the Gustave Roussy Cancer Campus in Villejuif, France and colleagues on 1 March 2021 in the Journal of Clinical Oncology.

ROS1 fusions are found in 1-2% of NSCLC where it is considered a distinct disease subtype. Up to 40% of patients with ROS1 fusion–positive metastatic NSCLC have CNS metastases at diagnosis. To maximise efficacy, novel targeted agents must demonstrate activity in the CNS.

The authors wrote in the background that a tyrosine kinase inhibitor (TKI) crizotinib is approved as first-line treatment for metastatic ROS1 fusion–positive NSCLC. However, crizotinib has poor CNS penetration and is actively exported from the CNS by P-glycoprotein. Furthermore, almost half of patients with ROS1 fusion–positive NSCLC who receive crizotinib experience first progression solely in the CNS. 

The small-molecule TKI entrectinib is a potent inhibitor of ROS1, specifically designed to cross the blood-brain barrier and remain active within the CNS. Contrary to crizotinib, preclinical models confirmed that entrectinib is a weak P-glycoprotein substrate and achieves high CNS concentrations, associated with strong efficacy in brain tumour models.

Based on positive findings from an integrated analysis of ALKA-372-001, STARTRK-1, STARTRK-2 with data cut-off on 31 May 2018, entrectinib was approved by the US Food and Drug Administration and the European Medicines Agency for patients with ROS1 fusion–positive NSCLC. The investigators now report in the Journal of Clinical Oncology updated efficacy and safety data for entrectinib in patients with ROS1 fusion–positive NSCLC, based on an integrated analysis of these three studies with more patients and longer follow-up. These updated data were also presented at the ESMO 2020 Virtual Congress.

The efficacy-evaluable population included adults with locally advanced or metastatic ROS1 fusion–positive NSCLC with or without CNS metastases who received entrectinib ≥600 mg orally once per day. Co-primary endpoints were objective response rate (ORR) assessed by blinded independent central review (BICR) and duration of response (DoR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), intracranial ORR, intracranial DoR, intracranial PFS, and safety.

In total, 161 patients with a follow-up of ≥ 6 months were evaluable. The median treatment duration was 10.7 months (IQR, 6.4-17.7).

The ORR was 67.1% (n = 108, 95% confidence interval [CI] 59.3 to 74.3), and responses were durable (12-month DoR rate, 63%, median DoR 15.7 months).

The 12-month PFS rate was 55% (median PFS 15.7 months), and the 12-month OS rate was 81% (median OS not estimable).

In 24 patients with measurable baseline CNS metastases by BICR, the intracranial ORR was 79.2% (n = 19; 95% CI 57.9 to 92.9), the median intracranial PFS was 12.0 months (95% CI 6.2 to 19.3), and the median intracranial DoR was 12.9 months (12-month rate, 55%).

The safety profile in this updated analysis was similar to that reported in the primary analysis, and no new safety signals were found.

The authors underlined that before entrectinib approval, there was an unmet need for a CNS-active treatment for patients with locally advanced or metastatic ROS1 fusion–positive NSCLC. They concluded that entrectinib continued to have strong overall and intracranial efficacy in these patients. The safety profile was consistent with previous reports.

The work was supported by F. Hoffmann-La Roche Ltd.

Reference

Dziadziuszko R, Krebs MG, de Barud F, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. Jounrla of Clinical Oncology; Published online 1 March 2021. DOI: 10.1200/JCO.20.03025.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...